WO2024094110A1 - 一种替马他赛化合物晶型及其制备方法和用途 - Google Patents
一种替马他赛化合物晶型及其制备方法和用途 Download PDFInfo
- Publication number
- WO2024094110A1 WO2024094110A1 PCT/CN2023/129288 CN2023129288W WO2024094110A1 WO 2024094110 A1 WO2024094110 A1 WO 2024094110A1 CN 2023129288 W CN2023129288 W CN 2023129288W WO 2024094110 A1 WO2024094110 A1 WO 2024094110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- temataxel
- crystal
- temperature
- crystal form
- solvent
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 title abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- 239000012065 filter cake Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 9
- 238000001953 recrystallisation Methods 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 14
- 229930012538 Paclitaxel Natural products 0.000 description 12
- 229960001592 paclitaxel Drugs 0.000 description 12
- 238000009826 distribution Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102220042174 rs141655687 Human genes 0.000 description 5
- 102220043159 rs587780996 Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 2
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- KOTXAHKUCAQPQA-AAUVPWARSA-N taxine Chemical compound C1([C@@H]([C@@H](O)C(=O)O[C@@H]2C=3/C[C@@](C([C@H](O)C4=C(C)[C@@H](OC(C)=O)CC(C4(C)C)[C@@H](OC(C)=O)\C=3)=O)(C)[C@@H](O)C2)N(C)C)=CC=CC=C1 KOTXAHKUCAQPQA-AAUVPWARSA-N 0.000 description 2
- 229930189271 taxine Natural products 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- YWLXLRUDGLRYDR-YLPZXOTFSA-N 10-dab iii Chemical compound O([C@H]1[C@@H]2[C@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@H](O)C[C@H]1OC[C@@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-YLPZXOTFSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 1
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
- 101100233916 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR5 gene Proteins 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Definitions
- the invention belongs to the field of medical technology, and specifically relates to a temataxel compound crystal form and a preparation method and use thereof.
- paclitaxel had a moderate anti-tumor effect on solid cancers such as human breast cancer and colon cancer.
- NCI National Cancer Institute
- 13 countries have approved paclitaxel for the treatment of cancer.
- Paclitaxel is considered to be the most significant discovery in the field of natural anticancer drug research in the past 15 years, bringing good news to cancer patients.
- paclitaxel Although paclitaxel has excellent anti-tumor effect, it binds to the N-terminal B-tubulin and promotes tubulin polymerization. This effect disturbs the dynamic balance between tubulin and microtubules, destroys the cancer cell division process, and induces cell arrest, causing cell death, thereby exerting an anti-cancer effect.
- the main problem in the application of paclitaxel is that its water solubility is too poor.
- we use some surfactants, polyoxyethylene castor oil and Tween 80 we use some surfactants, polyoxyethylene castor oil and Tween 80, but the side effects of polyoxyethylene sesame oil are very large. Polyoxyethylene sesame oil and Tween 80 can cause certain adverse reactions.
- Paclitaxel also has other disadvantages: poor water solubility, central nervous system toxicity, gastrointestinal adverse reactions, liver toxicity, etc. These disadvantages limit the clinical application of paclitaxel in the treatment of cancer. Moreover, the structure of paclitaxel is relatively complex, and the total synthesis process route is long, which is not conducive to large-scale industrial production.
- paclitaxel In order to overcome the shortcomings of paclitaxel, many people have modified its structure. Many paclitaxel-like compounds have been obtained. Among them, docetaxel, cabazitaxel and temataxel are semi-synthetic products of paclitaxel compounds. Their starting material is the inactive 10-DABIII extracted from the yew plant. The biological activity is improved by semi-synthetic structural modification, and finally paclitaxel analogs are obtained.
- the invention discloses a temataxel crystal, which is a crystal form A.
- the crystal form A uses a Cu-K ⁇ X-ray powder diffraction method, and a 2 ⁇ angle expressed in degrees has obvious diffraction peaks at 8.05 ⁇ 0.10, 8.40 ⁇ 0.10, 8.70 ⁇ 0.1, 9.60 ⁇ 0.10, 13.29 ⁇ 0.10 and 14.20 ⁇ 0.10.
- the crystalline form A uses a Cu-K ⁇ X-ray powder diffraction method, and the 2 ⁇ angle expressed in degrees has obvious diffraction peaks at 7.10 ⁇ 0.10, 8.05 ⁇ 0.10, 8.40 ⁇ 0.10, 8.70 ⁇ 0.1, 9.60 ⁇ 0.10, 13.29 ⁇ 0.10, 14.20 ⁇ 0.10, 14.76 ⁇ 0.10 and 18.48 ⁇ 0.10.
- the crystalline form A uses a Cu-K ⁇ X-ray powder diffraction method, and the 2 ⁇ angle expressed in degrees is 5.83 ⁇ 0.10, 7.10 ⁇ 0.10, 8.05 ⁇ 0.10, 8.40 ⁇ 0.10, 8.70 ⁇ 0.1, 9.60 ⁇ 0.10, 10.58 ⁇ 0.10, 13.29 ⁇ 0.10, 14.20 ⁇ 0.10, 14.76 ⁇ 0.10, 15.45 ⁇ 0.10, 16.90 ⁇ 0.10, 17.30 ⁇ 0.10, 18.48 ⁇ 0.10, 20.43 ⁇ 0.10 and 21.53 ⁇ 0.10. There are obvious diffraction peaks.
- the crystalline form A has a powder X-ray diffraction pattern substantially as shown in Figure 1.
- the melting point of the crystalline form A is 202.5-203°C.
- the crystal characteristics of the crystal form A are mainly reflected by infrared spectrum, melting point, DSC and TGA.
- the crystalline form A has a DSC thermal spectrum and an infrared spectrum substantially as shown in FIG. 2 and/or FIG. 3 .
- a method for preparing temataxel crystal form A which specifically comprises: adding temataxel crude product and solvent A into a reaction bottle, stirring until completely dissolved, heating the system to reflux for dissolution, and then cooling according to the following system program: 1) reducing the temperature from 60° C. to 50° C. in 1.5 ⁇ 0.2 h; 2) reducing the temperature from 50° C. to 40° C. in 1 ⁇ 0.2 h; 3) reducing the temperature from 40° C. to 30° C. in 0.5 ⁇ 0.1 h;
- the specific steps of the preparation method are: adding crude temataxel and solvent A to a reaction bottle, stirring until completely dissolved, heating the system to reflux to dissolve, and then cooling according to the following system procedure:
- the solvent A is at least one of anhydrous ethanol, isopropanol, methanol and acetonitrile; the solvent A is preferably anhydrous ethanol.
- the solvent B is at least one of ethyl acetate, n-hexane and n-heptane; preferably, the solvent B is ethyl acetate.
- the specific steps of the preparation method are:
- the filter cake can be dried by forced air drying at 45°C.
- the specific preparation process of the temataxel crystal form A is shown in FIG4 .
- the invention discloses use of temataxel crystals in preparing medicines for treating advanced breast cancer and ovarian cancer.
- a pharmaceutical composition comprising a pharmaceutically effective amount of the temataxel crystal form A according to claim 1 and a pharmaceutically acceptable excipient.
- the present invention studies the crystal forms of the temataxel compound, examines the crystal forms of the temataxel compound precipitated in different solvents, provides data support for the later development of drug dosage forms through the crystal form research, and performs DSC and TGA detection and analysis on the temataxel crystal form A.
- the temataxel crystal form A obtained by the present invention has large crystal particles, is easier to separate solid and liquid during the filtration process, has a short drying time, is suitable for industrialization, and saves purification costs.
- the preparation process of the technical solution of the present invention adopts programmed cooling and strictly controls the cooling rate to avoid the mixed crystal state. Appear.
- the temataxel A obtained by the invention has better purity, no residual solvent, and meets the raw material pharmaceutical standards.
- FIG1 is an X-ray powder diffraction spectrum of Tematacept Form A obtained in Example 1 of the present invention.
- FIG2 is a DSC spectrum of Tematacept Form A obtained in Example 1 of the present invention.
- FIG3 is an infrared spectrum of Tematacept Form A obtained in Example 1 of the present invention.
- FIG. 4 is a schematic diagram of the preparation process of Tematasele Form A according to an embodiment of the present invention.
- Tematasire Form A The preparation process of Tematasire Form A in the following examples can be referred to FIG4 .
- XRPD The XRPD spectra of all the embodiments of the present invention were detected by XRD6500 X-ray diffractometer of Shimadzu Corporation of Japan at room temperature, with 2 ⁇ angle scanning from 5 degrees to 40 degrees, Cu-K ⁇ , and scanning speed: 2 degrees/minute.
- DSC The DSC spectra of all the embodiments of the present invention were detected by a DSC8500 differential scanning calorimeter produced by PerkinElmer, USA, with a nitrogen atmosphere and a heating rate of 10 degrees Celsius per minute.
- IR The infrared spectra of all the embodiments of the present invention were detected by a Nicolet-Magna FT-IR750 infrared spectrometer from Nicolet Corporation of the United States at room temperature, and the detection range was: 4000-350 cm -1 wavenumber.
- the temataxel obtained in Examples 1-3 of the present invention has higher yield, higher purity, lower production cost, and lower residual solvent, and meets pharmaceutical standards.
- the impurity removal effect of the recrystallization process of the crystal of the present invention was determined by high performance liquid chromatography. The test results are shown in Table 1.
- the crystal of the present invention has a better impurity removal effect than the amorphous crystal.
- the present invention provides a temataxel compound crystal form and a preparation method and use thereof.
- the temataxel compound crystal form A is obtained by recrystallization from at least one of ethyl acetate, anhydrous ethanol, isopropanol, methanol and acetonitrile.
- the obtained temataxel crystal form A has large crystal particles, is easier to separate solid and liquid during the filtration process, has a short drying time, high stability, and presents a single crystal form, has higher purity, and has better stability, and has good economic value and application prospects.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种替马他赛化合物晶型及其制备方法和用途。所述替马他赛化合物晶型A是通过乙酸乙酯、无水乙醇、异丙醇、甲醇和乙腈中的至少一种进行重结晶得到。制得的替马他赛晶型A的晶体颗粒大,过滤过程更容易固液分离,干燥时间短、稳定性高,且呈现单一晶型,具有更高的纯度,同时具备更优的稳定性。
Description
交叉引用
本申请要求2022年11月3日提交的专利名称为“一种替马他赛化合物晶型及其制备方法和用途”的第2022113707763号中国专利申请的优先权,其全部公开内容通过引用整体并入本文。
本发明属于医药技术领域,具体地涉及替马他赛化合物晶型及其制备方法和用途。
早在1856年Lucas就从浆果红豆杉(Taxus baccata L.)的叶片中提取出粉末状碱性部分,即紫杉碱(taxine)之后日本、美国分别进行了多方面的研究。1962年美国农业部(USDA)收集大量短叶红豆杉(Taxus brevifolia Nutt.)的树皮并进行了研究,1969年确定了该树皮中对KB细胞具有细胞毒性的有效成分为紫杉碱(Paclitaxel,商品名Taxol)Wall及其合作者于1971年首次从短叶红豆杉的树皮中分离到紫杉醇并确定了其结构。1983年美国国立癌症研究所(NCI)报告紫杉醇对人乳腺癌、结肠癌等实体癌有中等抗肿瘤作用。目前已有13个国家批准紫杉醇可用于癌症的治疗。紫杉醇被认为是近15年来天然抗癌药物研究领域最重大的发现,为广大癌症患者带来了福音。
紫杉醇抗肿瘤作用虽然极好,紫杉醇结合N-端的B-的微管蛋白并且促进微管蛋白聚合。这种作用扰乱了微管蛋白与微管的动态平衡,破坏了癌细胞分裂过程,通过诱导阻滞细胞,致使细胞死亡,从而发挥抗癌作用。然而紫杉醇的应用中的主要问题是其水溶性太差,临床应用时为了加大其水溶性,我们采用了一些表面活性剂,聚氧乙烯蓖麻油和吐温80,但聚氧乙烯葩麻油的副作用很大。聚氧乙烯葩麻油和吐温80会引起一定的不良反应。紫杉醇还有其他的缺点:水溶性太差、神经中枢毒性、胃肠道不良反应、肝脏毒性等。这些缺点限制了紫杉醇在治疗癌症方面的临床应用。而且紫杉醇结构相对复杂,全合成工艺路线长,不利于大规模工业化生产。
为了克服紫杉醇的缺点许多人对其结构进行了修饰。人们研究得到了许多紫杉醇类似的化合物。其中多西他赛、卡巴他赛及替马他赛等都是紫杉醇化合物的半合成产品。它们的起始原料是从紫杉植物中提取的没有活性的10-DABIII,通过半合成结构修饰改善生物活性,最终获取紫杉醇类似物。
替马他赛结构修饰后作为一种新的化合物,其制备专利CN102241648B介绍了其合
成路线及耐药性实验,目前没有关于替马他赛晶型研究专利报道。
发明内容
替马他赛结构:
本发明公开一种替马他赛晶体,其为晶型A,所述晶型A使用Cu-Kα的X-射线粉末衍射方法,以度表示的2θ角在8.05±0.10、8.40±0.10、8.70±0.1、9.60±0.10、13.29±0.10和14.20±0.10处有明显的衍射峰。
在一些实例中,所述晶型A使用Cu-Kα的X-射线粉末衍射方法,以度表示的2θ角在7.10±0.10、8.05±0.10、8.40±0.10、8.70±0.1、9.60±0.10、13.29±0.10、14.20±0.10、14.76±0.10和18.48±0.10处有明显的衍射峰。
在一些实例中,所述晶型A使用Cu-Kα的X-射线粉末衍射方法,以度表示的2θ角在5.83±0.10、7.10±0.10、8.05±0.10、8.40±0.10、8.70±0.1、9.60±0.10、10.58±0.10、13.29±0.10、14.20±0.10、14.76±0.10、15.45±0.10、16.90±0.10、17.30±0.10、18.48±0.10、20.43±0.10和21.53±0.10处有明显的衍射峰。在一些实例中,所述晶型A具有基本上如图1所示的粉末X-射线衍射图。
在一些实例中,所述晶型A的熔点为202.5~203℃。
在一些实例中,所述晶型A在3200~3400cm-1处为-OH的特征峰吸收,2900-3100cm-1处为-CH3、-CH2-的特征吸收峰,1750cm-1处为-C=O的特征吸收峰;1600cm-1处及与1580cm-1处为苯环的特征吸收峰。
所述晶型A的晶型特点主要通过红外图谱,熔点,DSC,TGA体现。
在一些实例中,所述晶型A具有基本上如图2和/或图3所示的DSC热谱、红外光谱。
一种替马他赛晶型A制备方法,其具体为:向反应瓶中加入替马他赛粗品、溶剂A,搅拌未全溶,体系升温至回流溶解,然后按照如下体系程序降温:1)用1.5±0.2h将温度自60℃降至50℃;2)用1±0.2h将温度自50℃降至40℃;3)用0.5±0.1h将温度自40℃降至30℃;
优选的,所述制备方法的具体步骤为:向反应瓶中加入替马他赛粗品、溶剂A,搅拌未全溶,体系升温至回流溶解,然后按照如下体系程序降温:
1)用1.5±0.1h将温度自60℃降至50℃;
2)用1±0.1h将温度自50℃降至40℃;
3)用0.5±0.1h将温度自40℃降至30℃;
4)温度降至20-30℃,向体系中加入溶剂B搅拌析晶,20-30℃保温析晶1~2h,体系过滤收集白色固体得粗产物,滤饼干燥至恒重,得到替马他赛晶型A。
所述溶剂A为无水乙醇、异丙醇、甲醇和乙腈中的至少一种;溶剂A优选为无水乙醇。
所述溶剂B为乙酸乙酯,正己烷,正庚烷中的至少一种;溶剂B优选为乙酸乙酯。
在一个优选的实施方案中,所述制备方法的具体步骤为:
向反应瓶中加入替马他赛粗品、无水乙醇搅拌未全溶,体系升温至回流溶解,然后按照如下体系程序降温:
1)用1.5±0.1h将温度自60℃降至50℃;
2)用1±0.1h将温度自50℃降至40℃;
3)用0.5±0.1h将温度自40℃降至30℃;
4)温度降至20-30℃,向体系中加入乙酸乙酯搅拌析晶,20-30℃保温析晶1~2h,体系过滤收集白色固体得粗产物,滤饼干燥至恒重,得到替马他赛晶型A。
所述滤饼干燥可采用45℃鼓风干燥。
在一些实例中,所述替马他赛晶型A的具体制备流程如图4所示。
本发明公开替马他赛晶体在制备治疗乳腺癌晚期、卵巢癌的药物中的用途。
一种药物组合物,其包含药物有效量的权利要求1所述的替马他赛晶型A以及药学上可接受的赋形剂。
本发明对替马他赛化合物晶型进行了研究,考察在不同溶剂中析出替马他赛化合物晶型,通过晶型研究为后期药物剂型开发提供数据支持,且对替马他赛晶型A进行DSC及TGA检测分析。
DSC及TGA数据显示,本发明技术方案所得替马他赛晶型稳定性高,且呈现单一晶型。稳定性比无定型高。
本发明所得替马他赛晶型A晶体颗粒大,过滤过程更容易固液分离,干燥时间短。适宜产业化。节约纯化成本。
本发明技术方案所的制备过程,采用程序降温,严格控制降温速率,避免混晶状态
出现。
本发明所得替马他赛A具有更好的纯度,无残留溶剂,符合原料药用标准。
图1为本发明实施例1所得替马他赛晶型A的X-射线粉末衍射谱图。
图2为本发明实施例1所得替马他赛晶型A的DSC谱图。
图3为本发明实施例1所得替马他赛晶型A的红外光谱图。
图4为本发明实施例替马他赛晶型A的制备流程示意图。
以下实施例用于说明本发明,但不用来限制本发明的范围。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购买得到的常规产品。
以下实施例替马他赛晶型A的制备流程可参考图4。
实验条件:
XRPD:本发明所有实施例的XRPD谱图由日本岛沣公司的XRD6500X射线衍射仪于室温检测,2θ角扫描从5度到40度,Cu-Kα,扫描速度:2度/分钟。
DSC:本发明所有实施例的DSC谱图由美国铂金埃尔默公司的DSC8500差示扫描量热仪检测,气氛为氮气,加热速度为10摄氏度/分钟。
IR:本发明所有实施例的红外谱图由美国尼高力公司的Nicolet-MagnaFT-IR750红外光谱仪于室温检测,检测范围为:4000-350厘米-1的波数。
实施例1乙酸乙酯/乙醇体系
取替马他赛粗品10g加入70ml无水乙醇搅拌,体系未全溶,体系升温至回流,体系溶清,用1.5h将温度自60℃降至50℃,再用1.5h将温度自50℃降至40℃,最后用0.5h将温度自40℃降至30℃,向体系中加入140ml乙酸乙酯,搅拌析晶1h,过滤,45℃烘干得1#替马他赛晶型A,产量9.8g,产率98%;
X-射线粉末衍射谱图见图1、DSC谱图见2;测试的粒径分布为D50=230μm,D90=250μm。
实施例2正己烷/甲醇体系
取替马他赛粗品10g加入70ml无水甲醇搅拌,体系未全溶,体系升温至回流,体系溶清,用1.5h将温度自60℃降至50℃,再用1h将温度自50℃降至40℃,最后用0.5h将温度自40℃降至30℃,向体系中加入140ml正己烷,搅拌析晶1h,过滤,45℃烘干得2#替
马他赛晶型A,产量9.5g,产率95%;
测试的粒径分布为D50=200μm,D90=240μm。
实施例3正庚烷/乙腈体系
取替马他赛粗品10g加入100ml乙腈搅拌,体系未全溶,体系升温至回流,体系溶清,用1.5h将温度自60℃降至50℃,再用1h将温度自50℃降至40℃,最后用0.5h将温度自40℃降至30℃,向体系中加入140ml正庚烷,搅拌析晶1h,过滤,45℃烘干得3#替马他赛晶型A,产量9.3g,产率93%;
测试的粒径分布为D50=200μm,D90=220μm。
对比例1
取替马他赛粗品10g加入70ml无水乙醇加热回流溶解,用1.5h将温度自60℃降至50℃,再用1h将温度自50℃降至40℃未析出固体,体系保持40℃减压浓缩,溶剂浓缩旋干得到9.8g类白色固体D1#替马他赛块状固体(无定型态)溶剂化合物(乙醇残留量为2.3%),产量9.8g,收率98%。测试的粒径分布为D50=80μm,D90=120μm。
对比例2
取替马他赛粗品10g加入70ml无水甲醇加热回流溶解,体系搅拌冰浴降温快速降温至0℃析出固体,体系过滤烘干得到8.5g类D2#白色固体替马他赛溶剂化合物(甲醇残留量1.0%),产量8.5g,产率85%。测试的粒径分布为D50=70μm,D90=160μm。
对比例3
取替马他赛粗品10g加入70ml无水乙醇搅拌,体系未全溶,体系升温至回流,体系溶清,自然降至室温,向体系中加入140ml乙酸乙酯,搅拌析晶1h,过滤,45℃烘干得替马他赛晶型A,产量7.4g,产率74%。测试的粒径分布为D50=70μm,D90=200μm。
与对比实施例1和2相比,本发明实施例1-3所得替马他赛的收率更高,纯度更高,生产成本低;溶残低,符合药用标准。
试验例1重结晶的杂质除去效果
采用高效液相色谱测定本发明晶体的重结晶工序的杂质除去效果,测试结果见表1。
表1
根据以上结果,本发明晶体与无定型相比,杂质除去效果更好。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
本发明提供一种替马他赛化合物晶型及其制备方法和用途。所述替马他赛化合物晶型A是通过乙酸乙酯、无水乙醇、异丙醇、甲醇和乙腈中的至少一种进行重结晶得到。制得的替马他赛晶型A的晶体颗粒大,过滤过程更容易固液分离,干燥时间短、稳定性高,且呈现单一晶型,具有更高的纯度,同时具备更优的稳定性,具有较好的经济价值和应用前景。
Claims (10)
- 一种替马他赛晶体,其为晶型A,所述晶型A使用Cu-Kα的X-射线粉末衍射方法,以度表示的2θ角在8.05±0.10、8.40±0.10、8.70±0.1、9.60±0.10、13.29±0.10和14.20±0.10处有明显的衍射峰。
- 根据权利要求1所述的替马他赛晶体,其特征在于,所述晶型A使用Cu-Kα的X-射线粉末衍射方法,以度表示的2θ角在7.10±0.10、8.05±0.10、8.40±0.10、8.70±0.1、9.60±0.10、13.29±0.10、14.20±0.10、14.76±0.10和18.48±0.10处有明显的衍射峰。
- 根据权利要求1或2所述的替马他赛晶体,其特征在于,所述晶型A使用Cu-Kα的X-射线粉末衍射方法,以度表示的2θ角在5.83±0.10、7.10±0.10、8.05±0.10、8.40±0.10、8.70±0.1、9.60±0.10、10.58±0.10、13.29±0.10、14.20±0.10、14.76±0.10、15.45±0.10、16.90±0.10、17.30±0.10、18.48±0.10、20.43±0.10和21.53±0.10处有明显的衍射峰。
- 根据权利要求1-3任一项所述的替马他赛晶体,其特征在于,所述晶型A具有基本上如图1所示的粉末X-射线衍射图。
- 根据权利要求1-4任一项所述的替马他赛晶体,其特征在于,所述晶型A的熔点为202.5~203℃。
- 根据权利要求1-5任一项所述的替马他赛晶体,其特征在于,所述晶型A在3200~3400cm-1,2900-3100cm-1,1750cm-1,1600cm-1与1580cm-1有特征吸收。
- 根据权利要求1-6任一项所述的替马他赛晶体,其特征在于,所述晶型A具有基本上如图2所示的DSC热谱;和/或,所述晶型A具有基本上如图3所示的红外光谱。
- 权利要求1-7任一项所述的替马他赛晶型A的制备方法,其特征在于,所述制备方法中包含程序降温的步骤,所述程序降温的步骤包括;1)用1.5±0.2h将温度自60℃降至50℃;2)用1±0.2h将温度自50℃降至40℃;3)用0.5±0.1h将温度自40℃降至30℃;优选的,所述制备方法的具体步骤为:向反应瓶中加入替马他赛粗品、溶剂A搅拌未全溶,体系升温至回流溶解,然后按照如下体系程序降温:1)用1.5±0.1h将温度自60℃降至50℃;2)用1±0.1h将温度自50℃降至40℃;3)用0.5±0.1h将温度自40℃降至30℃;4)温度降至20-30℃,向体系中加入溶剂B搅拌析晶,20-30℃保温析晶1~2h,体系过滤收集白色固体得粗产物,滤饼干燥至恒重,得到替马他赛晶型A;所述溶剂A为无水乙醇、异丙醇、甲醇和乙腈中的至少一种;溶剂A优选为无水乙醇;所述溶剂B为乙酸乙酯,正己烷,正庚烷中的至少一种;溶剂B优选为乙酸乙酯。
- 一种药物组合物,其包含药物有效量的权利要求1-7任一项所述替马他赛晶型A以及药学上可接受的赋形剂。
- 权利要求1-7任一项所述替马他赛晶型A在制备治疗乳腺癌晚期、卵巢癌药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211370776.3A CN115925654A (zh) | 2022-11-03 | 2022-11-03 | 一种替马他赛化合物晶型及其制备方法和用途 |
CN202211370776.3 | 2022-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024094110A1 true WO2024094110A1 (zh) | 2024-05-10 |
Family
ID=86654943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/129288 WO2024094110A1 (zh) | 2022-11-03 | 2023-11-02 | 一种替马他赛化合物晶型及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115925654A (zh) |
WO (1) | WO2024094110A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115925654A (zh) * | 2022-11-03 | 2023-04-07 | 北京诺康达医药科技股份有限公司 | 一种替马他赛化合物晶型及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102241648A (zh) * | 2011-01-31 | 2011-11-16 | 复旦大学 | 抗多药耐药紫杉烷类衍生物及其制备方法和应用 |
CN104710389A (zh) * | 2013-12-14 | 2015-06-17 | 苏州雷纳药物研发有限公司 | 一种纯化紫杉烷类衍生物的方法 |
CN115925654A (zh) * | 2022-11-03 | 2023-04-07 | 北京诺康达医药科技股份有限公司 | 一种替马他赛化合物晶型及其制备方法和用途 |
-
2022
- 2022-11-03 CN CN202211370776.3A patent/CN115925654A/zh active Pending
-
2023
- 2023-11-02 WO PCT/CN2023/129288 patent/WO2024094110A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102241648A (zh) * | 2011-01-31 | 2011-11-16 | 复旦大学 | 抗多药耐药紫杉烷类衍生物及其制备方法和应用 |
CN104710389A (zh) * | 2013-12-14 | 2015-06-17 | 苏州雷纳药物研发有限公司 | 一种纯化紫杉烷类衍生物的方法 |
CN115925654A (zh) * | 2022-11-03 | 2023-04-07 | 北京诺康达医药科技股份有限公司 | 一种替马他赛化合物晶型及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
SUMEI REN: "Synthesis and biological evaluation of novel larotaxel analogues", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 156, 1 August 2018 (2018-08-01), AMSTERDAM, NL , pages 692 - 710, XP093168933, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.07.029 * |
Also Published As
Publication number | Publication date |
---|---|
CN115925654A (zh) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2024094110A1 (zh) | 一种替马他赛化合物晶型及其制备方法和用途 | |
US8357811B2 (en) | Crystalline forms of docetaxel and process for preparation thereof | |
JP4451660B2 (ja) | パクリタキセル溶媒化合物 | |
KR20070088784A (ko) | 도세탁셀의 결정형 및 이의 제조 방법 | |
JP6457658B2 (ja) | 安定した、溶媒和物が含まれないアプレミラスト結晶形ii、及びその製造方法 | |
MXPA06004363A (es) | Forma polimorfica de la n-[(r)-2, 3-dihidroxipropoxi]-3, 4-difluoro-2 -(2-fluoro-4- yodofenilamino) benzamida. | |
SK13712001A3 (sk) | C7 esterom substituované taxány ako protinádorové látky | |
CN111574421B (zh) | 2,3,4-三取代四氢吡咯烷类化合物及其制备方法和应用 | |
CN112624985A (zh) | 一种复合物晶体、制备方法及应用 | |
CN112028896A (zh) | 阿卡替尼的新晶型及其制备方法 | |
CN112409183A (zh) | 山椒子烯酮及其衍生物、其制备方法和应用 | |
CN106279169B (zh) | 一种伊曲茶碱新晶型及其制备方法 | |
CN110041320B (zh) | 一种阿齐沙坦的结晶的制备方法 | |
CN109438370B (zh) | 一种甲基吡嗪衍生物无水晶型 | |
CN110143934B (zh) | 一种含氟紫杉烷类化合物及其制备方法与应用 | |
TW201932463A (zh) | 吳茱萸鹼之製造方法 | |
EP2114910A1 (en) | A novel crystalline mycophenolate sodium polymorph and processes to manufacture same | |
CN111689947B (zh) | 替加氟-l-脯氨酸共晶体及其制备方法 | |
CN113620911A (zh) | 一种紫杉醇衍生物及其制备方法 | |
WO2011158058A1 (en) | α-CRYSTALLINE FORM OF CARBABENZPYRIDE | |
WO2023124408A1 (zh) | 利可君的晶型及其制备方法、用途 | |
CN111217824B (zh) | 4-o-芳氨丙基土甘草a衍生物及其制备及应用 | |
KR20050059132A (ko) | 신규 결정 | |
WO2017031994A1 (zh) | 曲沙他滨的合成及其晶型 | |
EP3960742A1 (en) | Crystals of alkynyl-containing compound, salt and solvate thereof, preparation method, and applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23885036 Country of ref document: EP Kind code of ref document: A1 |